Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II comparison of MER-101 versus Zometa in bisphosphonate-naive hormone-refractory prostate cancer with bone metastases
2008-001395-74Phase 2Completed
- Sponsor
- Merrion Pharmaceuticals
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoledronic acid in prostate cancer (PCa) (3 arms), sponsored by Merrion Pharmaceuticals. Primary endpoints: Urine NTX biomarker response, Serum CTX biomarker response and 2 more. Started May 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-001395-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001395-74.